IBD LIVE Series - Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa

Heba Iskandar; Julia B. Greer; Alyssa M. Krasinskas; Andrew T. Tinsley; Walter A. Koltun; Corey A. Siegel; L. Campbell Levy; Hans H. Herfarth; Francis A. Farraye; David G. Binion; Joel R. Rosh; David J. Keljo; Kim L. Isaacs; Miguel D. Regueiro

doi:10.1097/MIB.0000000000001266

IBD LIVE Series - Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa

Heba Iskandar, Julia B. Greer, Alyssa M. Krasinskas, Andrew T. Tinsley, Walter A. Koltun, Corey A. Siegel, L. Campbell Levy, Hans H. Herfarth, Francis A. Farraye, David G. Binion, Joel R. Rosh, David J. Keljo, Kim L. Isaacs, Miguel D. Regueiro

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	1667-1677
Number of pages	11
Journal	Inflammatory bowel diseases
Volume	23
Issue number	10
DOIs	https://doi.org/10.1097/MIB.0000000000001266
State	Published - Oct 1 2017

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Gastroenterology

Access to Document

10.1097/MIB.0000000000001266

Cite this

Iskandar, H., Greer, J. B., Krasinskas, A. M., Tinsley, A. T., Koltun, W. A., Siegel, C. A., Levy, L. C., Herfarth, H. H., Farraye, F. A., Binion, D. G., Rosh, J. R., Keljo, D. J., Isaacs, K. L., & Regueiro, M. D. (2017). IBD LIVE Series - Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa. Inflammatory bowel diseases, 23(10), 1667-1677. https://doi.org/10.1097/MIB.0000000000001266

@article{991bb6f6ff994d92ac3e06d3a2e9c48e,

title = "IBD LIVE Series - Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa",

author = "Heba Iskandar and Greer, {Julia B.} and Krasinskas, {Alyssa M.} and Tinsley, {Andrew T.} and Koltun, {Walter A.} and Siegel, {Corey A.} and Levy, {L. Campbell} and Herfarth, {Hans H.} and Farraye, {Francis A.} and Binion, {David G.} and Rosh, {Joel R.} and Keljo, {David J.} and Isaacs, {Kim L.} and Regueiro, {Miguel D.}",

note = "Funding Information: H. Iskandar has consulted for UCB and AbbVie. J. B. Greer holds a grant from AbbVie. A. T. Tinsley has previously consulted for Janssen Pharmaceutica and is involved in ongoing consulting and lecturing for AbbVie. C. A. Siegel serves as a consultant to AbbVie, Amgen, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Takeda, UCB, has delivered CME activities to American Regent, AbbVie, Janssen, Pfizer, Takeda, and has received grant support from AbbVie, Janssen, Pfizer, and Takeda. H. H. Herfarth receives consulting fees from Pfizer, Celltrion, Samsung, Merck, and UCB. F. A. Farraye serves on the Advisory Boards of AbbVie, Braintree Labs, Janssen, Merck, Pfizer, Salix, and Takeda; is a member of the DSMB for Mesoblast and Protagonist; receives book royalties from Jones and Bartlett and Slack; and is a shareholder of Cellceutix. D. G. Binion has grant support from Janssen, Merck, and UCB and has received honoraria from Janssen, AbbVie, and Synthetic Biologics. J. R. Rosh serves as a consultant to and has received grant support from AbbVie and Janssen. K. L. Isaacs consults on the Data Safety Monitoring Board for Medimmune and Janssen. M. D. Regueiro serves on the Advisory Boards and consults for AbbVie, Janssen, Pfizer, Takeda, and UCB. The remaining authors have no conflict of interest to disclose.",

year = "2017",

month = oct,

day = "1",

doi = "10.1097/MIB.0000000000001266",

language = "English (US)",

volume = "23",

pages = "1667--1677",

journal = "Inflammatory bowel diseases",

issn = "1078-0998",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

Iskandar, H, Greer, JB, Krasinskas, AM, Tinsley, AT , Koltun, WA, Siegel, CA, Levy, LC, Herfarth, HH, Farraye, FA, Binion, DG, Rosh, JR, Keljo, DJ, Isaacs, KL & Regueiro, MD 2017, 'IBD LIVE Series - Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa', Inflammatory bowel diseases, vol. 23, no. 10, pp. 1667-1677. https://doi.org/10.1097/MIB.0000000000001266

TY - JOUR

T1 - IBD LIVE Series - Case 8

T2 - Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa

AU - Iskandar, Heba

AU - Greer, Julia B.

AU - Krasinskas, Alyssa M.

AU - Tinsley, Andrew T.

AU - Koltun, Walter A.

AU - Siegel, Corey A.

AU - Levy, L. Campbell

AU - Herfarth, Hans H.

AU - Farraye, Francis A.

AU - Binion, David G.

AU - Rosh, Joel R.

AU - Keljo, David J.

AU - Isaacs, Kim L.

AU - Regueiro, Miguel D.

N1 - Funding Information: H. Iskandar has consulted for UCB and AbbVie. J. B. Greer holds a grant from AbbVie. A. T. Tinsley has previously consulted for Janssen Pharmaceutica and is involved in ongoing consulting and lecturing for AbbVie. C. A. Siegel serves as a consultant to AbbVie, Amgen, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Takeda, UCB, has delivered CME activities to American Regent, AbbVie, Janssen, Pfizer, Takeda, and has received grant support from AbbVie, Janssen, Pfizer, and Takeda. H. H. Herfarth receives consulting fees from Pfizer, Celltrion, Samsung, Merck, and UCB. F. A. Farraye serves on the Advisory Boards of AbbVie, Braintree Labs, Janssen, Merck, Pfizer, Salix, and Takeda; is a member of the DSMB for Mesoblast and Protagonist; receives book royalties from Jones and Bartlett and Slack; and is a shareholder of Cellceutix. D. G. Binion has grant support from Janssen, Merck, and UCB and has received honoraria from Janssen, AbbVie, and Synthetic Biologics. J. R. Rosh serves as a consultant to and has received grant support from AbbVie and Janssen. K. L. Isaacs consults on the Data Safety Monitoring Board for Medimmune and Janssen. M. D. Regueiro serves on the Advisory Boards and consults for AbbVie, Janssen, Pfizer, Takeda, and UCB. The remaining authors have no conflict of interest to disclose.

PY - 2017/10/1

Y1 - 2017/10/1

UR - http://www.scopus.com/inward/record.url?scp=85029765159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029765159&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000001266

DO - 10.1097/MIB.0000000000001266

M3 - Article

C2 - 28906288

AN - SCOPUS:85029765159

SN - 1078-0998

VL - 23

SP - 1667

EP - 1677

JO - Inflammatory bowel diseases

JF - Inflammatory bowel diseases

IS - 10

ER -

IBD LIVE Series - Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this